1. Home
  2. |Insights
  3. |Dismissal, Says Who? Recent Seventh and Ninth Circuit Decisions Offer Competing Views on DOJ’s Dismissal Authority under the False Claims Act, But Congress May Have the Last Word

Dismissal, Says Who? Recent Seventh and Ninth Circuit Decisions Offer Competing Views on DOJ’s Dismissal Authority under the False Claims Act, But Congress May Have the Last Word

Client Alert | 2 min read | 09.18.20

In the span of only two weeks last month, the U.S. Courts of Appeals for the Seventh Circuit and the Ninth Circuit became the first two Circuit Courts to issue decisions on lower court’s denials of Government dismissal requests pursuant to its authority under the False Claims Act (FCA), 31 U.S.C. 3730(c)(2)(A). As discussed in greater detail in Crowell & Moring’s Feature Comment in the Government Contractor entitled “You Win Some, You Lose Some: In Wake Of Ninth Circuit Defeat, The Government Gets A Big Win From Seventh Circuit Ruling Expanding Its Dismissal Authority Over FCA Qui Tam Actions” available here, there is now further disagreement among the Courts and within the Government itself regarding the extent of the Government’s dismissal authority under the FCA.

There are several key takeaways from the decisions and dialog between Congress and the Department of Justice for consideration when analyzing whether the Government will exercise its dismissal authority in a FCA action.

  • The Seventh Circuit’s decision in United States v. UCB, Inc., 970 F.3d 835 (7th Cir. 2020) adds a third approach to the existing circuit split headlined by the D.C. Circuit in Swift v. U.S., 318 F.3d 250 (D.C. Cir. 2003), and Ninth Circuit in U.S. ex rel. Sequoia Orange Co. v. Baird-Neece Packing Corp., 151 F.3d 1139 (9th Cir. 1998) on how courts should assess the Government’s statutory right to dismiss qui tam cases.
  • UCB is favorable for defendants in that the Seventh Circuit agreed with the D.C. Circuit that the Government should have a nearly unassailable right to dismiss qui tam cases brought in the Government’s name by relators.
  • The Seventh Circuit complicated the Government’s path to seek dismissal by requiring it to first intervene in the case, adding an administrative burden and requiring good cause for intervention when the Government seeks to dismiss after initially declining to intervene.
  • Senator Chuck Grassley (R-Iowa), a vocal opponent of the view that the Government has unfettered dismissal authority, is said to be working on legislation to restrict the Government’s right to dismiss qui tam actions, an action that could resolve the growing circuit split without intervention by the Supreme Court.

For additional commentary on these developments, see Crowell & Moring’s Feature Comment in the Government Contractor available here or contact any of the attorneys in this alert.

Insights

Client Alert | 9 min read | 10.21.26

Artificial Intelligence in Life Sciences: Reliability of AI-Generated Evidence in Drug Discovery and Development

The life sciences sector is uniquely vulnerable to the inherent risks of AI-generated evidence in drug development and discovery. This client alert focuses on five core challenges: hallucinations, skewed predictions from unrepresentative training data, the opacity of AI reasoning, input sensitivity that undermines reproducibility, and adversarial manipulation of training data. To address these risks, companies should use experimental validation and human oversight as the common legal and regulatory safety net. This entails among other measures auditing AI outputs, characterizing training data, and structural oversight. Companies also should prepare for evolving frameworks and guidance from the U.S. Food and Drug Administration (FDA) and the European Union (EU) that address use of AI in drug discovery and development .  ...